全文获取类型
收费全文 | 67948篇 |
免费 | 6025篇 |
国内免费 | 209篇 |
专业分类
耳鼻咽喉 | 544篇 |
儿科学 | 2661篇 |
妇产科学 | 1892篇 |
基础医学 | 9765篇 |
口腔科学 | 1252篇 |
临床医学 | 9517篇 |
内科学 | 13691篇 |
皮肤病学 | 1391篇 |
神经病学 | 6997篇 |
特种医学 | 1570篇 |
外国民族医学 | 4篇 |
外科学 | 6216篇 |
综合类 | 543篇 |
一般理论 | 66篇 |
预防医学 | 7856篇 |
眼科学 | 940篇 |
药学 | 3982篇 |
2篇 | |
中国医学 | 73篇 |
肿瘤学 | 5220篇 |
出版年
2023年 | 594篇 |
2022年 | 777篇 |
2021年 | 1934篇 |
2020年 | 1460篇 |
2019年 | 2163篇 |
2018年 | 2391篇 |
2017年 | 1866篇 |
2016年 | 2027篇 |
2015年 | 2146篇 |
2014年 | 2719篇 |
2013年 | 3877篇 |
2012年 | 5297篇 |
2011年 | 5317篇 |
2010年 | 3047篇 |
2009年 | 2721篇 |
2008年 | 4399篇 |
2007年 | 4484篇 |
2006年 | 4301篇 |
2005年 | 4053篇 |
2004年 | 3892篇 |
2003年 | 3538篇 |
2002年 | 3201篇 |
2001年 | 541篇 |
2000年 | 428篇 |
1999年 | 508篇 |
1998年 | 741篇 |
1997年 | 566篇 |
1996年 | 484篇 |
1995年 | 473篇 |
1994年 | 380篇 |
1993年 | 367篇 |
1992年 | 263篇 |
1991年 | 243篇 |
1990年 | 218篇 |
1989年 | 186篇 |
1988年 | 183篇 |
1987年 | 127篇 |
1986年 | 152篇 |
1985年 | 149篇 |
1984年 | 161篇 |
1983年 | 159篇 |
1982年 | 193篇 |
1981年 | 186篇 |
1980年 | 141篇 |
1979年 | 89篇 |
1978年 | 99篇 |
1977年 | 88篇 |
1976年 | 93篇 |
1975年 | 71篇 |
1974年 | 72篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
102.
Dr. Andrew G. Bostom M.D. Dr. Anne L. Hume Pharm.D. Dr. Charles B. Eaton M.D. Dr. Joseph P. Laurino Ph.D. Ms. Lisa R. Yanek B.A. Ms. Mary S. Regan B.S. Mr. William H. McQuade M.P.H. Dr. Wendy Y. Craig Ph.D. Ms. Gayle Perrone M.B.A. Dr. Paul F. Jacques Sc.D. 《Pharmacotherapy》1995,15(4):458-464
Study Objective . To determine the efficacy of high-dose ascorbate supplementation in lowering lipoprotein(a) [Lp(a)] levels in patients with premature coronary heart disease (CHD). Design . Randomized, double-blind, placebo-controlled trial. Setting . Outpatient clinic. Patients . Forty-four patients with documented premature CHD. defined as confirmed myocardial infarction and/or angiographically determined stenosis of 50% or greater in at least one major coronary artery before age 60 years. Interventions . Patients were block randomized on the basis of age, gender, and screening Lp(a) concentrations to receive ascorbate 4.5 g/day or placebo for 12 weeks. Measurements and Main Results . High-dose ascorbate was well tolerated and produced a marked elevation in mean plasma ascorbate levels (+1.2 mg/dl; p<0.001). Multiple linear regression analysis revealed no significant effect of supplementation on postintervention Lp(a) levels (p=0.39) in a model that included treatment group assignment, and baseline Lp(a) levels. Conclusions . Our findings do not support a clinically important lowering effect of high-dose ascorbate on plasma Lp(a) in patients with premature CHD. 相似文献
103.
Anne Rannard Deborah Buck David E J Jones Oliver F W James Ann Jacoby 《Clinical gastroenterology and hepatology》2004,2(2):164-174
BACKGROUND AND AIMS: Assessment of health-related quality of life (HRQOL) is not routinely reported in the literature on chronic liver disease (CLD). Few studies have examined quality of life (QOL) in patients with primary biliary cirrhosis (PBC) despite its significant functional impact. One of the reasons for the lack of HRQOL measurement in patients with PBC may be the absence of a well-recognized and widely used measure that clinicians can use in ordinary clinical practice. The aim of this study is to evaluate HRQOL measures used in patients with PBC and examine the suitability of the measures for these patients. METHODS: A literature search identified reports that focused on any aspect of QOL in patients with PBC. Key texts were identified containing generic, domain-specific, and condition-specific measures. The identified measures were systematically evaluated for appropriateness, acceptability, reliability, validity, precision, and responsiveness. RESULTS: Twenty measures were identified from 9 key texts. Six of the measures were previously validated generic measures; 10 were domain-specific measures previously used to measure fatigue, depression, and psychological distress in general and psychiatric populations; and 4 measures had been developed in patients with CLD. Reporting of reliability and validity generally was consistent for all measures used. However, reporting of the remaining criteria was variable, particularly in relation to responsiveness over time and acceptability of the measures to patients with PBC. CONCLUSIONS: A clearer and more rigorous approach is needed in reporting the properties of HRQOL measures used in patients with PBC to help clinicians decide which measures are most suitable for these patients. 相似文献
104.
ANAPHYLAXIS IS A SEVERE SYSTEMIC ALLERGIC reaction that is potentially fatal. It requires prompt recognition and immediate management. Anaphylaxis has a rapid onset with multiple organ–system involvement and is mostly caused by specific antigens in sensitized individuals. Reactions typically follow a uniphasic course, however, 20% will be biphasic in nature. The second phase usually occurs after an asymptomatic period of 1–8 hours, but there may be a 24-hour delay. Protracted anaphylaxis may persist beyond 24 hours. Concurrent β-blocker therapy may adversely affect the response to management. Epinephrine is the treatment of choice and should be administered immediately. Secondary measures include circulatory support, H1 and H2 antagonists, corticosteroids and, occasionally, bronchodilators. Post-treatment observation of these patients is necessary, and they should remain within ready access of emergency care for the following 48 hours. 相似文献
105.
106.
Chairat Shayakul Petr Jarolim Marie Zachlederova Daniel Prabakaran Dionisio Cortez-Campeao Dana Kalabova Alan K Stuart-Tilley Hiroshi Ideguchi Christlieb Haller Seth L Alper 《Nephrology, dialysis, transplantation》2004,19(2):371-379
BACKGROUND: Mutations in the human SLC4A1 (AE1/band 3) gene are associated with hereditary spherocytic anaemia and with distal renal tubular acidosis (dRTA). The molecular diagnosis of AE1 mutations has been complicated by the absence of highly polymorphic genetic markers, and the pathogenic mechanisms of some dRTA-associated AE1 mutations remain unclear. Here, we characterized a polymorphic dinucleotide repeat close to the human AE1 gene and performed an immunocytochemical study of kidney tissue from a patient with inherited dRTA with a defined AE1 mutation. METHODS: One CA repeat region was identified in a phage P1-derived artificial chromosome (PAC) clone containing most of the human AE1 gene and the upstream flanking region. We determined its heterozygosity value in multiple populations by PCR analysis. Genotyping of one family with dominant dRTA identified the AE1 R589H mutation, and family member genotypes were compared with the CA repeat length. AE1 and vH(+)-ATPase polypeptides in kidney tissue from an AE1 R589H patient were examined by immunocytochemistry for the first time. RESULTS: This CA repeat, previously reported as D17S1183, is approximately 90 kb upstream of the AE1 gene and displayed considerable length polymorphism, with small racial differences, and a heterozygosity value of 0.56. The allele-specific length of this repeat confirmed co-segregation of the AE1 R589H mutation with the disease phenotype in a family with dominant dRTA. Immunostaining of the kidney cortex from one affected member with superimposed chronic pyelonephritis revealed vH(+)-ATPase-positive intercalated cells in which AE1 was undetectable, and proximal tubular epithelial cells with apparently enhanced apical vH(+)-ATPase staining. CONCLUSIONS: The highly polymorphic dinucleotide repeat adjacent to the human AE1 gene may be useful for future studies of disease association and haplotype analysis. Intercalated cells persist in the end-stage kidney of a patient with familial autosomal dominant dRTA associated with the AE1 R589H mutation. The absence of detectable AE1 polypeptide in those intercalated cells supports the genetic prediction that the AE1 R589H mutation indeed causes dominant dRTA. 相似文献
107.
108.
Anne Andermann 《Canadian Medical Association journal》2007,176(12):1738-1739
109.
Nhân Pham-Thi Pierre Scheinmann Riad Fadel Anne Combebias Claude Andre the Study Group 《Pediatric allergy and immunology》2007,18(1):47-57
Although several studies have demonstrated the efficacy of subcutaneous immunotherapy in allergic asthma, few have shown the same benefit using sublingual immunotherapy (SLIT) in asthmatic patients. This study was conducted to assess the efficacy of house dust mite (HDM) SLIT in addition to allergen avoidance and standard pharmacologic treatment. A double-blind, placebo-controlled trial was performed in 111 children (aged 5-15 yr) with HDM-induced mild-to-moderate asthma. After a 4-week baseline phase, patients were randomly assigned to receive SLIT with tablets of HDM extract (n = 55) or placebo (n = 56) for 18 months. Pharmacologic treatment was adjusted every 3 months following a step-down approach. Asthma symptom scores, reduction in use of inhaled corticosteroids and inhaled beta(2)-agonists, rhinitis symptoms, lung function tests, skin sensitivity to HDM, dust mite-specific immunoglobulin (Ig) E and IgG(4), and quality of life (QoL) were assessed during the study. After 18 months of treatment, diurnal and nocturnal asthma symptoms scores did not show significant differences between SLIT and placebo groups. Inhaled corticosteroids and inhaled beta(2)-agonists use was reduced in both groups without significant differences between groups. There were no significant differences in lung function (forced expiratory volume in 1 s and peak flow rate variations) between groups. Rhinitis symptom score decreased in both groups, with no difference between the two groups. The severity dimension of QoL was significantly improved in the SLIT group (age 6-12 yr). SLIT induced a significant reduction of skin sensitivity to HDM (p < 0.01) and a significant increase in HDM-specific IgE and IgG(4) antibodies (p < 0.001) in the SLIT group compared with the placebo group. SLIT was well tolerated with mild/moderate local adverse events. No severe systemic reactions were reported. This study indicates that, when mild-moderate asthmatic children are optimally controlled by pharmacologic treatment and HDM avoidance, SLIT does not provide additional benefit, despite a significant reduction in allergic response to HDM. Under such conditions, only a complete, but ethically unfeasible, discontinuation of inhaled corticosteroid would have demonstrated a possible benefit of SLIT. 相似文献
110.
Marilyn Anne Murphy M.S. 《Journal of medical systems》1986,10(2):109-120
This paper identifies the need for more specific guidelines in preparing faculty to use and develop computer-based instructional materials. Cory's model for faculty development is described and planning considerations are outlined. Finally, components of this multifaceted approach to faculty development—identifying available resources, emphasizing the current uses of computers, providing computer literacy/faculty awareness sessions, focusing on the instructional use of microcomputers, collaboration, and communication—are discussed. 相似文献